Room Temperature Stable PspA-Based Nanovaccine Induces Protective Immunity

Area of Science:

• Vaccinology
• Nanotechnology
• Microbiology

Background:

• Streptococcus pneumoniae causes pneumonia, a leading cause of death in young children.
• Current vaccines lack protection against all pneumococcal serotypes.
• Pneumococcal surface protein A (PspA) is a promising antigen for broad-spectrum vaccines.

Purpose of the Study:

• To develop a stable, single-dose PspA-based nanovaccine.
• To evaluate the efficacy and stability of the nanovaccine formulation.
• To overcome limitations of existing pneumococcal vaccines.

Main Methods:

• Designed a biodegradable polyanhydride nanovaccine encapsulating PspA.
• Administered a single dose of the nanovaccine to mice.
• Challenged immunized mice with S. pneumoniae and assessed survival rates.
• Evaluated nanovaccine stability after 60 days of room temperature storage.

Main Results:

• The PspA nanovaccine significantly increased survival rates compared to soluble PspA.
• The nanovaccine showed efficacy with a 25-fold lower protein dose.
• Formulation was stable for 60 days at room temperature without cold chain requirements.
• Nanovaccine induced protective immunity with reduced tissue reactogenicity.

Conclusions:

• A single-dose PspA nanovaccine provides effective protection against S. pneumoniae.
• The nanovaccine formulation offers thermal stability, eliminating cold chain needs.
• This approach presents a promising strategy for next-generation pneumococcal vaccines.